JANUS KINASE INHIBITOR
Rinvoq is a prescription medication approved by the Food and Drug Administration (FDA) to treat moderate-to-severe rheumatoid arthritis in adults who have not responded adequately to Methotrexate. Rinvoq is also known by its drug name, Upadacitinib.
Rinvoq is an immunomodulator, or in other words, a drug that modulates the immune system. Rinvoq is believed to work by inhibiting Janus kinases, proteins involved in signaling the immune system to attack the connective tissues.
How do I take it?
Rinvoq is taken orally once a day.
Rinvoq is an extended-release tablet.
The FDA-approved label for Rinvoq lists common side effects including upper respiratory infections, nausea, cough, and fever.
Rare but serious side effects listed for Rinvoq can include serious infections, blood clots, gastrointestinal tract perforations, and increased risk of developing certain types of cancer.
For more information, visit:
Rinvoq - AbbVie